As we demonstrated that Trop2 is a prognostic tissue biomarker for clinically significant prostate cancer and is associated with worse clinical features, suggesting the great potential of Trop2 targeted therapy as a therapeutic strategy for metastatic prostate cancer. This evidence concerns the gene TACSTD2 and prostate cancer.